APLT Logo

Applied Therapeutics, Inc. (APLT) 

NASDAQ$0.5464+0.03 (5.84%)
Market Cap
$59.74M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
455 of 924
Rank in Industry
266 of 527

APLT Insider Trading Activity

APLT Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$6,720,81716100

Related Transactions

Chinoporos ConstantineSee Remarks0$02$17,348$-17,348
Hansard AdamChief Commercial Officer0$01$263,415$-263,415
Funtleyder Leslie D.Chief Financial Officer0$05$327,452$-327,452
Perfetti RiccardoChief Medical Officer0$05$881,585$-881,585
ALEXANDRIA REAL ESTATE EQUITIES, INC.10 percent owner0$02$1.27M$-1.27M
Shendelman ShoshanaPresident and CEO0$05$6.7M$-6.7M

About Applied Therapeutics, Inc.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III â€¦

Insider Activity of Applied Therapeutics, Inc.

Over the last 12 months, insiders at Applied Therapeutics, Inc. have bought $0 and sold $6.72M worth of Applied Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Applied Therapeutics, Inc. have bought $661,035 and sold $8.75M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 30,000 shares for transaction amount of $65,367 was made by Kanter Stacy J. (director) on 2023‑12‑01.

List of Insider Buy and Sell Transactions, Applied Therapeutics, Inc.

2025-03-04SalePerfetti RiccardoChief Medical Officer
10,366
0.0081%
$0.44$4,561+6.39%
2025-03-04SaleFuntleyder Leslie D.See Remarks
14,502
0.0114%
$0.44$6,381+6.39%
2025-03-04SaleChinoporos ConstantineSee Remarks
447
0.0004%
$0.44$197+6.39%
2025-02-06SalePerfetti RiccardoChief Medical Officer
86,078
0.0743%
$0.61$52,508-10.83%
2025-02-06SaleFuntleyder Leslie D.See Remarks
22,950
0.0198%
$0.61$14,000-10.83%
2025-02-06SaleChinoporos ConstantineSee Remarks
28,117
0.0243%
$0.61$17,151-10.83%
2024-08-22SalePerfetti RiccardoChief Medical Officer
22,681
0.0206%
$5.83$132,230-68.75%
2024-08-22SaleFuntleyder Leslie D.Chief Financial Officer
13,530
0.0123%
$5.83$78,880-68.75%
2024-08-14SaleShendelman ShoshanaPresident and CEO
119,591
0.1056%
$5.93$709,175-20.78%
2024-08-13SaleShendelman ShoshanaPresident and CEO
357,423
0.3288%
$6.18$2.21M-22.20%
2024-08-12SaleShendelman ShoshanaPresident and CEO
300,000
0.267%
$5.98$1.79M-16.30%
2024-06-06SaleShendelman ShoshanaPresident and CEO
61,795
0.0519%
$4.32$266,954+13.33%
2024-06-06SalePerfetti RiccardoChief Medical Officer
22,003
0.0185%
$4.32$95,053+13.33%
2024-06-06SaleFuntleyder Leslie D.Chief Financial Officer
16,980
0.0143%
$4.32$73,354+13.33%
2024-06-05SaleALEXANDRIA REAL ESTATE EQUITIES, INC.10 percent owner
150,000
0.1261%
$4.24$636,000+15.16%
2024-06-04SaleALEXANDRIA REAL ESTATE EQUITIES, INC.10 percent owner
150,000
0.131%
$4.21$631,500+20.38%
2024-03-14SaleShendelman ShoshanaPresident and CEO
318,573
0.2652%
$5.39$1.72M-16.07%
2024-03-14SalePerfetti RiccardoChief Medical Officer
110,804
0.0922%
$5.39$597,234-16.07%
2024-03-14SaleHansard AdamChief Commercial Officer
48,871
0.0407%
$5.39$263,415-16.07%
2024-03-14SaleFuntleyder Leslie D.Chief Financial Officer
28,727
0.0239%
$5.39$154,839-16.07%
Total: 130
*Gray background shows transactions not older than one year

Insider Historical Profitability

18.42%
ALEXANDRIA REAL ESTATE EQUITIES, INC.10 percent owner
5855077
5.032%
$3.01M26+18.45%
Shendelman ShoshanaPresident and CEO
4690839
4.0315%
$2.41M615+32.95%
Perfetti RiccardoChief Medical Officer
890409
0.7652%
$457,135.98161<0.0001%
MARCUS JOEL Sdirector
365360
0.314%
$187,575.8223+10.6%
Kanter Stacy J.director
63000
0.0541%
$32,344.2030+15.24%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$2,942,496
100
17.32%
$66.91M
$6,787,959
35
49.84%
$60.62M
$22,110,933
34
30.18%
$67.48M
$459,011,221
33
33.04%
$57.94M
$144,247,213
29
10.15%
$64.24M

APLT Institutional Investors: Active Positions

Increased Positions86+59.31%41M+36.28%
Decreased Positions67-46.21%38M-33.86%
New Positions42New3MNew
Sold Out Positions43Sold Out8MSold Out
Total Postitions164+13.1%115M+2.42%

APLT Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vestal Point Capital, Lp$5,900.009.91%11.5M+10M+904.37%2024-12-31
Vr Adviser, Llc$5,125.008.61%9.99M+165,591+1.69%2024-12-31
Propel Bio Management, Llc$4,933.008.29%9.62M+3M+46.4%2024-12-31
Blackrock, Inc.$4,769.008.01%9.3M+2M+33.9%2024-12-31
Morgan Stanley$4,522.007.6%8.82M-1M-10.99%2024-12-31
Schonfeld Strategic Advisors Llc$4,495.007.55%8.76M+8M+2,458.26%2024-12-31
Knoll Capital Management, Llc$2,975.005%5.8M+225,000+4.04%2024-12-31
Vanguard Group Inc$2,846.004.78%5.55M+305,282+5.82%2024-12-31
T. Rowe Price Investment Management, Inc.$2,781.004.67%5.42M+5M+2,511.86%2024-12-31
Deutsche Bank Ag$2,292.003.85%4.47M+30,520+0.69%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.